Abstract 2192 Bortezomib is a proteasome inhibitor known to affect multiple signaling
pathways., The inhibition of nuclear factor KB (NF-KB) activation and the induction of …

We explored the safety and efficacy of bortezomib given as single agent in patients with
untreated or relapsed/refractory acute myeloid leukemia (AML), unfit for conventional …

Abstract 3595 The overexpression of proteasomes and constitutive activation of NF-KB in
acute myeloid leukemia (AML) cells suggest that proteasome inhibitors (PI) such as …

Abstract MEC (mitoxantrone, etoposide, cytarabine) is a standard regimen for
relapsed/refractory (R/R) acute myeloid leukemia (AML), but outcomes remain poor. The …

Conventional therapy for acute myeloid leukemia (AML) consists of a combination of
cytarabine and an anthracycline such as idarubicin. Currently, most patients ultimately fail …

In vitro experiments have shown that the addition of a proteasome inhibitor to an
anthracycline results in synergistic cytotoxicity to leukemia cells and, specifically, the …

Purpose: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro. We
conducted this phase I study to determine if the proteasome inhibitor bortezomib could be …

Abstract 331 We previously demonstrated that bortezomib can be safely added to induction
chemotherapy in patients with AML. We conducted a clinical trial in order to determine (a) …

Captivating bortezomib: an active but still mysterious drug. - Abstract - Europe PMC Sign in |
Create an account https://orcid.org Europe PMC Menu About Tools Developers Help …

Abstract 4140 In vitro studies conducted by our group have shown that proteasome
inhibition induced cytotoxicity both in cell lines as well as fresh cells obtained from AML …